Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It

Eli Lilly (LLY) is trending, with shares up 4.8% over the past month, though lagging the S&P 500's 7.2% gain. Current quarter EPS is projected at $5.56, a 41.8% year-over-year increase, while revenue is estimated at $14.47 billion, up 28% year-over-year; fiscal year EPS is expected to increase 69%. Despite strong growth projections, Lilly holds a Zacks Rank #3, suggesting near-term performance in line with the broader market.

Analysis

Eli Lilly (LLY) has demonstrated notable investor interest, with its stock returning +4.8% over the past month, outperforming the Zacks Large Cap Pharmaceuticals industry's +2.1% gain but trailing the S&P 500 composite's +7.2% change. The company exhibits strong growth prospects, with earnings for the current quarter projected at $5.56 per share, a significant +41.8% year-over-year increase, and the Zacks Consensus Estimate for this period has risen by +0.5% in the last 30 days. For the current fiscal year, EPS is anticipated to surge by +69% to $21.95, although this estimate has seen a slight -0.6% downward revision recently. Similarly, the next fiscal year's EPS is forecast at $30.77, a +40.2% increase, with a minor -0.2% revision in the past month. Revenue growth forecasts are also robust: current quarter sales are estimated at $14.47 billion (+28% YoY), with current and next fiscal year revenues projected at $59.92 billion (+33% YoY) and $72.43 billion (+20.9% YoY) respectively. In its last reported quarter, Lilly posted revenues of $12.73 billion (+45.2% YoY), surpassing estimates by +0.86%, though EPS of $3.34 missed the consensus by -5.11%. Over the past four quarters, Lilly has surpassed consensus EPS estimates twice and revenue estimates three times. Despite compelling growth metrics, the stock holds a Zacks Rank #3 (Hold), suggesting its near-term performance may align with the broader market, supported by a Zacks Value Style Score of C, indicating it trades at par with its peers.

Key Decisions for Investors

• Given Eli Lilly's Zacks Rank #3 (Hold) and recent stock underperformance relative to the S&P 500, investors might consider maintaining current positions rather than aggressively accumulating, as the stock is expected to perform in line with the market in the near term.
• Investors should closely monitor upcoming earnings reports for a return to consistent EPS beats, especially in light of the recent -5.11% EPS surprise miss and slight downward revisions to full-year earnings estimates, despite strong top-line growth.
• While long-term growth projections for both revenue and earnings remain very strong, the 'C' grade for value suggests the stock is fairly valued relative to peers; therefore, entry points should be carefully considered, balancing growth against current valuation.